Wilmington, DE, United States of America

Reid Huber



Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Reid Huber: Innovator in Cancer Treatment

Introduction

Reid Huber is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of cancer treatment, particularly in relation to breast cancer. His innovative work focuses on the modulation of Her-2 cleavage, which plays a crucial role in tumor cell proliferation.

Latest Patents

Reid Huber holds one patent titled "Compositions, methods and kits relating to Her-2 cleavage." This invention pertains to compositions, methods, and kits based on the ADAM-mediated cleavage of Her-2. The patent outlines treatments for cancer, specifically breast cancer, by modulating this cleavage. It also highlights the surprising synergistic effect between the inhibition of Her-2 cleavage by an ADAM and certain cytostatic and cytotoxic compounds, such as Herceptin and Taxol, in inhibiting tumor cell proliferation and inducing cell death. Additionally, the patent introduces novel variants of ADAM15, designated as ADAM15 variant 1 and ADAM15 variant 2.

Career Highlights

Reid Huber is associated with Incyte Corporation, where he continues to advance his research and innovations in cancer treatment. His work has the potential to significantly impact therapeutic strategies for patients suffering from breast cancer.

Collaborations

Reid collaborates with esteemed colleagues, including Steven M Friedman and Peggy Ann Scherle, to further enhance the research and development of cancer treatments.

Conclusion

Reid Huber's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to improving patient outcomes. His work in modulating Her-2 cleavage is a testament to the potential of targeted therapies in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…